MLYS (Mineralys Therapeutics) ROC (Joel Greenblatt) %: -518,171.43% (As of Mar. 2026)


MLYS Mineralys Therapeutics Inc MLYS
35 GF Score
Price $27.68
! 2 Warning Signs
View Full Analysis

What is Mineralys Therapeutics ROC (Joel Greenblatt) %?

Mineralys Therapeutics MLYS +2.98% 35 ROC (Joel Greenblatt) % is -518,171.43% as of Mar. 2026. GuruFocus rates MLYS with a GF Score™ of 35/100. The stock has 2 warning signs investors should review. Among 1,321 Biotechnology companies, Mineralys Therapeutics ranks worse than 99.62% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Mineralys Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -518,171.43%.

The historical rank and industry rank for Mineralys Therapeutics's ROC (Joel Greenblatt) % or its related term are showing as below:

MLYS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -625901.46   Med: -18263.22   Max: -4121.57
Current: -625901.46

During the past 6 years, Mineralys Therapeutics's highest ROC (Joel Greenblatt) % was -4121.57%. The lowest was -625901.46%. And the median was -18263.22%.

MLYS's ROC (Joel Greenblatt) % is ranked worse than
99.62% of 1321 companies
in the Biotechnology industry
Industry Median: -296.6 vs MLYS: -625901.46

Mineralys Therapeutics's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Mineralys Therapeutics  (NAS:MLYS) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Mineralys Therapeutics ROC (Joel Greenblatt) % Related Terms


Mineralys Therapeutics ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Mineralys Therapeutics's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mineralys Therapeutics ROC (Joel Greenblatt) % Chart

Mineralys Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial 0.00 0.00 -4,121.57 -18,263.22 -374,953.85

Mineralys Therapeutics Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -390,742.86 -623,280.00 -1,134,648.28 -680,533.33 -518,171.43

MLYS vs VCEL, NRIX, PHVS: ROC (Joel Greenblatt) % Comparison

For the Biotechnology subindustry, Mineralys Therapeutics's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mineralys Therapeutics ROC (Joel Greenblatt) % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mineralys Therapeutics's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Mineralys Therapeutics's ROC (Joel Greenblatt) % falls into.


MLYS
35GF Score
Mineralys Therapeutics Inc MLYS
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mineralys Therapeutics ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 4.751) - (9.573 + 0 + 5.54)
=-10.362

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 6.4100000000001) - (12.406 + 0 + 2.312)
=-8.3079999999999

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Mineralys Therapeutics for the quarter that ended in Mar. 2026 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-181.36/( ( (0.038 + max(-10.362, 0)) + (0.032 + max(-8.3079999999999, 0)) )/ 2 )
=-181.36/( ( 0.038 + 0.032 )/ 2 )
=-181.36/0.035
=-518,171.43 %

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of -518,171.43% mean?
Mineralys Therapeutics (MLYS) has a ROC (Joel Greenblatt) % of -518,171.43% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Mineralys Therapeutics and its competitors. According to the industry distribution chart, Mineralys Therapeutics ranks #1316 out of 1321 companies in the Biotechnology industry, placing it in the top 99.6%.
Is Mineralys Therapeutics' ROC (Joel Greenblatt) % too high?
Mineralys Therapeutics' current ROC (Joel Greenblatt) % is -518,171.43%. Based on the distribution chart, Mineralys Therapeutics ranks #1316 out of 1321 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Mineralys Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Mineralys Therapeutics' ROC (Joel Greenblatt) % compare to VCEL and NRIX?
According to the Biotechnology industry distribution chart, Mineralys Therapeutics ranks #1316 out of 1321 companies for ROC (Joel Greenblatt) %. This places Mineralys Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Mineralys Therapeutics and its competitors. Mineralys Therapeutics's current ROC (Joel Greenblatt) % is -518,171.43%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mineralys Therapeutics stock overvalued right now?
Mineralys Therapeutics (MLYS) has a current ROC (Joel Greenblatt) % of -518,171.43%. The current ROC (Joel Greenblatt) % is -518,171.43%. Mineralys Therapeutics' overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Mineralys Therapeutics (MLYS), the current ROC (Joel Greenblatt) % is -518,171.43% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mineralys Therapeutics Business Description

Address 150 North Radnor Chester Road, Suite F200, Radnor, PA, USA, 19087
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.
35GF Score

Get the complete analysis for MLYS

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$27.68
Price